Abstract
Bolstering its immuno-oncology pipeline, Merck & Co. will pay roughly $135 million to acquire the German biotech firm Rigontec. The deal adds RNA-based therapies targeting the retinoic acid-inducible gene I (RIG-I) pathway, a component of the innate immune system, and includes a RIG-I agonist in Phase I studies as a cancer treatment. Investors in Rigontec, which was spun off of the University of Bonn in 2014, could receive another $415 million if certain milestones are reached.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.